The latest price target for Amgen (NASDAQ:AMGN) was reported by Wolfe Research on November 15, 2024. The analyst firm set a price target for $0.00 expecting AMGN to fall to within 12 months (a possible -100.00% downside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Amgen (NASDAQ:AMGN) was provided by Wolfe Research, and Amgen initiated their peer perform rating.

The last upgrade for Amgen Inc happened on May 3, 2024 when William Blair raised their price target to N/A. William Blair previously had a market perform for Amgen Inc.

The last downgrade for Amgen Inc happened on October 14, 2024 when Truist Securities changed their price target from $320 to $333 for Amgen Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amgen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amgen was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Amgen (AMGN) rating was a initiated with a price target of $0.00 to $0.00. The current price Amgen (AMGN) is trading at is $287.87, which is out of the analyst’s predicted range.